Abstract
The role of maintenance therapy after first-line platinum and pemetrexed for malignant pleural mesothelioma is unknown. We performed the first-to-date randomized trial to determine if continuation of pemetrexed would improve progression-free survival over that of observation and found that primary endpoint was not different between study arms. Therefore, we cannot recommend pemetrexed continuation maintenance for treatment of malignant pleural mesothelioma.
Original language | English |
---|---|
Pages (from-to) | 553-561.e1 |
Journal | Clinical Lung Cancer |
Volume | 21 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2020 |
Keywords
- Continuation pemetrexed
- Phase II study
- Progression-free survival
- Unresectable mesothelioma